Please check your internet connection and try again.
## Norepinephrine (Levophed)
### Overview
Norepinephrine is a potent alpha-adrenergic agonist with some beta-1 adrenergic activity. It primarily causes vasoconstriction, leading to an increase in systemic vascular resistance and blood pressure.
### Primary Indications
* Treatment of severe hypotension and shock unresponsive to adequate fluid resuscitation.
### Adult Dosing
* **Administration:** Intravenous (IV) infusion.
* **Initial Dose:** Typically initiated at 2 to 10 mcg/min.
* **Titration:** Gradually titrated to achieve the target blood pressure (e.g., mean arterial pressure [MAP] of 65 mmHg or higher, or specific target based on patient condition and local protocol). Doses may range from 0.01 to 3 mcg/kg/min in critically ill patients.
* **Maximum Dose:** No absolute maximum dose, titration guided by patient response and adverse effects.
### Pediatric Dosing
* **Administration:** Intravenous (IV) infusion.
* **Initial Dose:** Typically initiated at 0.05 to 0.1 mcg/kg/min.
* **Titration:** Titrated to achieve target MAP or other hemodynamic goals, often up to 1 mcg/kg/min, though higher doses (up to 2 mcg/kg/min) may be used in refractory shock.
### Dose Adjustments
* **Renal Impairment:** No specific dose adjustment recommended, but close monitoring is crucial.
* **Hepatic Impairment:** No specific dose adjustment recommended, but close monitoring is crucial.
### Contraindications
* Hypersensitivity to norepinephrine.
* Concurrent use with cyclopropane and halothane anesthetics (risk of severe hypertension and arrhythmias).
### Adverse Effects
* **Cardiovascular:** Arrhythmias (including bradycardia and tachycardia), hypertension, peripheral ischemia, reduced blood flow to vital organs, reflex bradycardia.
* **Extravasation:** Can cause severe tissue necrosis and sloughing. If extravasation occurs, stop the infusion immediately and infiltrate the area with an alpha-adrenergic blocking agent such as phentolamine.
### Key Drug Interactions
* **Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs):** Potentiate the pressor response; concurrent use is generally contraindicated or requires extreme caution and significant dose reduction of norepinephrine.
* **Anesthetics (volatile):** Increased risk of arrhythmias and severe hypertension.
* **Alpha-adrenergic Blockers (e.g., prazosin, phentolamine):** May antagonize the pressor effects.
* **Beta-adrenergic Blockers:** May lead to unopposed alpha-adrenergic stimulation, resulting in severe hypertension.
### Monitoring
* Continuous blood pressure monitoring (arterial line preferred).
* Heart rate and rhythm.
* Urine output.
* Central venous pressure (CVP) and/or pulmonary artery catheter (PAC) data if available.
* Peripheral perfusion and skin temperature.
* Infusion site for signs of extravasation.
### Clinical Pearls
* Norepinephrine is a potent vasoconstrictor and should be infused via a central venous catheter whenever possible to minimize the risk of peripheral tissue damage.
* Titrate slowly to the lowest effective dose to maintain target hemodynamic parameters.
* Rapid withdrawal can lead to a precipitous drop in blood pressure. Taper the infusion gradually.
* Consider concurrent use of other vasoactive agents or inotropes based on underlying cause of shock and patient response.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and institutional guidelines before administering any medication. Dosing and management may vary based on individual patient factors and clinical context.
